ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2011
MTSS1 overexpression correlates with poor prognosis in colorectal cancer.
Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- MTSS1: beyond the integration of actin and membrane dynamics.Cellular and molecular life sciences : CMLS · 2024Review
- Early and late stage MPN patients show distinct gene expression profiles in CD34Annals of hematology · 2021Article
- MTSS1 inhibits colorectal cancer metastasis by regulating the CXCR4/CXCL12 signaling axis.International journal of molecular medicine · 2021Article
- MTSS1 suppresses mammary tumor-initiating cells by enhancing RBCK1-mediated p65 ubiquitination.Nature cancer · 2020Article
- Review
- MTSS1 inhibits metastatic potential and induces G2/M phase cell cycle arrest in gastric cancer.OncoTargets and therapy · 2019Article
- MiR-423-5p in brain metastasis: potential role in diagnostics and molecular biology.Cell death & disease · 2018Article
- Missing-in-metastasis B (MIM-B) combined with caveolin-1 promotes metastasis of hepatocellular carcinoma.Oncotarget · 2017Article
- Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis.Oncogene · 2017Article
- Article
- MTSS1 is epigenetically regulated in glioma cells and inhibits glioma cell motility.Translational oncology · 2017Article
- Elevated MTSS1 expression associated with metastasis and poor prognosis of residual hepatitis B-related hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2016Article
- Expression and Significances of MTSS1 in Pancreatic Cancer.Pathology oncology research : POR · 2016Article
- MTSS1 suppresses cell migration and invasion by targeting CTTN in glioblastoma.Journal of neuro-oncology · 2015Article
- MTSS1 is an independent prognostic biomarker for survival in intrahepatic cholangiocarcinoma patients.American journal of translational research · 2015Article
- Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia.PloS one · 2015Article
- Expression of metastasis suppressor 1 in cervical carcinoma and the clinical significance.Oncology letters · 2014Article
- MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes.The Journal of clinical investigation · 2014Article
- Whole genome expression profiling of blood cells in ovarian cancer patients -prognostic impact of the CYP1B1, MTSS1, NCALD, and NOP14.Oncotarget · 2014Article
- Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis.Oncogene · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aims of this study were to investigate metastasis suppressor 1 (MTSS1) expression in benign and malignant colorectal tissues and to explore its significance in the prognosis of colorectal cancer (CRC) patients.
methodsMTSS1 expression was detected by immunohistochemistry in CRC, colorectal adenomatous polyp (precancerous lesion) and normal colorectal tissues. The relationship between MTSS1 expression in CRC tissues and clinicopathologic factors was analyzed with Mann-Whitney U test. MTSS1 protein expression was observed by Western blot in CRC tissues and adjacent nontumor colorectal tissues. Two factors between MTSS1 expression and CRC patient tumor node metastasis (TNM) stage were analyzed by Spearman rank correlation analysis. The Kaplan-Meier method and log-rank test were employed to compare the overall survival between MTSS1 negative/weak positive expression group and MTSS1 strong positive expression group.
resultsMTSS1 expression rates were significantly higher in CRC tissues (99 out of 135, 73.30%) than that in normal colorectal tissues (one out of seven, 14.29%), nontumor colorectal tissues (six out of 32, 18.75%), and adenomatous polyp tissues (four out of 15, 26.67%; P = 0.003, P < 0.001, P = 0.001, respectively). The upregulated MTSS1 expression in CRC tissues was significantly correlated to poor differentiation (P = 0.005), tissue invasion (P = 0.018), high preoperative CEA level (P = 0.022), present lymph node metastasis (P = 0.003), and high TNM stage (P = 0.002). MTSS1 expression was positively correlated with clinical TNM stage, that suggested the more advanced clinical TNM stage corresponding to the higher expression level of MTSS1 (r(s) = 0.327, P < 0.05). Western blotting demonstrated that MTSS1 expression was upregulated in 25 of 32 CRC tissues (75.0%) compared to corresponding adjacent nontumor colorectal tissues. The overall 5-year survival of MTSS1 strong positive expression CRC patients was significantly shorter than that of MTSS1 negative and weakly positive expression group. In multivariate analysis, MTSS1 expression maintained independent prognostic influence on overall survival (P = 0.004).
conclusionMTSS1 may be a good biomarker to be applied in the clinical setting to predict the prognosis of CRC patients with completely resected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.